



## Supplementary data


### (A) H1299



### (B) MDA-MB-231




### (C) MCF-7



**Figure S1.** Effect of Prostratin and GRC-2 on the cell viability of different types of cancer cells.


H1299, MDA-MB-231, and MCF-7 cells were treated with DMSO, prostratin, or GRC-2 for 72 h. Cell viability was determined by MTT assay. Results are presented as mean  $\pm$  S.E.M. (n = 3). \* $P$  < 0.05 and \*\* $P$  < 0.01 as compared with the vehicle control.




**Figure S2.** PKCs, PKD, and ERK expression are effectively reduced by using RNA interference.

A549 cells were transfected with lentiviral vectors encoding shRNA of interest or a control vector. The protein expression of PKC-δ, PKD, PKC-α, and ERK were detected by immunoblotting.

(A)



(B)



**Figure S3.** Effects of pharmacological inhibitors of PKC on the cytotoxicity caused by prostratin and GRC-2.

A549 cells were pretreated with Go6976 (0.1 μM) or GF109203 (1 μM) for 1 h, respectively. After then, cells were incubated with prostratin (3 μM) and GRC-2 (300 nM) for 72 h. The cell viability was measured by MTT assay. Results are presented as mean ± S.E.M. (n = 3). \*\*\* $P < 0.001$  as compared with the indicated groups.